Compile Data Set for Download or QSAR
maximum 50k data
Found 63 Enz. Inhib. hit(s) with all data for entry = 992
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301953(3-(3-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  0.190nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301980(3-(3-(4-(4-(Trifluoromethyl)pyrimidin-2-yl)piperaz...)
Affinity DataKi:  0.200nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301982(Ethyl 2-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piper...)
Affinity DataKi:  0.270nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301963(3-(3-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  0.290nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301984(Ethyl 2-(4-(3-(5-cyano-1H-indol-3-yl)propyl)pipera...)
Affinity DataKi:  0.300nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301967(3-(4-(4-(4-Methoxy-6-methylpyrimidin-2-yl)piperazi...)
Affinity DataKi:  0.650nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301978(3-(4-(4-(4-(Trifluoromethyl)pyrimidin-2-yl)piperaz...)
Affinity DataKi:  0.700nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301964(5-Chloro-3-(3-(4-(4,6-dimethylpyrimidin-2-yl)piper...)
Affinity DataKi:  0.710nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301983(Ethyl 2-(4-(4-(5-cyano-1H-indol-3-yl)butyl)piperaz...)
Affinity DataKi:  0.790nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301979(5-Fluoro-3-(3-(4-(4-(trifluoromethyl)pyrimidin-2-y...)
Affinity DataKi:  1nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301949(5-Chloro-3-(4-(4-(4,6-dimethoxypyrimidin-2-yl)pipe...)
Affinity DataKi:  1.10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301957(3-(4-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  1.10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301958(3-(4-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  1.10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301966(3-(3-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  1.10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301956(3-(3-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  1.30nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301948(3-(4-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  1.40nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301965(3-(3-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  1.40nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301968(3-(3-(4-(4-Methoxy-6-methylpyrimidin-2-yl)piperazi...)
Affinity DataKi:  1.5nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301960(3-(4-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  1.70nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301959(5-Chloro-3-(4-(4-(4,6-dimethylpyrimidin-2-yl)piper...)
Affinity DataKi:  1.80nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301954(5-Chloro-3-(3-(4-(4,6-dimethoxypyrimidin-2-yl)pipe...)
Affinity DataKi:  2nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301977(5-Fluoro-3-(4-(4-(4-(trifluoromethyl)pyrimidin-2-y...)
Affinity DataKi:  2nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301951(3-(4-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  2.30nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301992(2-(4-(3-(5-Cyano-1H-indol-3-yl)propyl)piperazin-1-...)
Affinity DataKi:  2.60nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301950(3-(4-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  2.80nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301961(3-(4-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  2.90nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301947(3-(4-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  3.30nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301955(3-(3-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  3.40nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301988(2-(4-(3-(5-Cyano-1H-indol-3-yl)propyl)piperazin-1-...)
Affinity DataKi:  3.70nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301971(2-(4-(3-(5-Fluoro-1H-indol-3-yl)propyl)piperazin-1...)
Affinity DataKi:  4nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301962(3-(3-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  4.10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301990(2-(4-(3-(5-Fluoro-1H-indol-3-yl)propyl)piperazin-1...)
Affinity DataKi:  4.20nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301986(2-(4-(3-(5-Fluoro-1H-indol-3-yl)propyl)piperazin-1...)
Affinity DataKi:  4.5nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301952(3-(3-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  4.80nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301991(2-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-y...)
Affinity DataKi:  5nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301981(Ethyl 2-(4-(4-(5-fluoro-1H-indol-3-yl)butyl)pipera...)
Affinity DataKi:  5.5nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301970(3-(4-(4-(4-Cyanopyrimidin-2-yl)piperazin-1-yl)buty...)
Affinity DataKi:  6.20nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301972(3-(3-(4-(4-Cyanopyrimidin-2-yl)piperazin-1-yl)prop...)
Affinity DataKi:  8nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301974(2-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-y...)
Affinity DataKi:  10nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301975(2-(4-(3-(5-Fluoro-1H-indol-3-yl)propyl)piperazin-1...)
Affinity DataKi:  12nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301987(2-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-y...)
Affinity DataKi:  12nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301976(2-(4-(3-(5-Cyano-1H-indol-3-yl)propyl)piperazin-1-...)
Affinity DataKi:  14nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301989(2-(4-(4-(5-Fluoro-1H-indol-3-yl)butyl)piperazin-1-...)
Affinity DataKi:  14nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301969(2-(4-(4-(5-Fluoro-1H-indol-3-yl)butyl)piperazin-1-...)
Affinity DataKi:  18nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301985(2-(4-(4-(5-Fluoro-1H-indol-3-yl)butyl)piperazin-1-...)
Affinity DataKi:  23nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 1A(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301973(2-(4-(4-(5-Fluoro-1H-indol-3-yl)butyl)piperazin-1-...)
Affinity DataKi:  60nMAssay Description:Human HEK-293 cell homogenates (36 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]8-OH-DPAT (Perkin-Elmer) in the absence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301962(3-(3-(4-(4,6-Dimethylpyrimidin-2-yl)piperazin-1-yl...)
Affinity DataKi:  110nMAssay Description:Cell membrane homogenates (24 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]methyl-spiperone in the absence or presence of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301950(3-(4-(4-(4,6-Dimethoxypyrimidin-2-yl)piperazin-1-y...)
Affinity DataKi:  110nMAssay Description:Cell membrane homogenates (24 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]methyl-spiperone in the absence or presence of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301981(Ethyl 2-(4-(4-(5-fluoro-1H-indol-3-yl)butyl)pipera...)
Affinity DataKi:  130nMAssay Description:Cell membrane homogenates (24 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]methyl-spiperone in the absence or presence of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Homo sapiens (Human))
Sunshine Lake Pharma

US Patent
LigandPNGBDBM301991(2-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-y...)
Affinity DataKi:  130nMAssay Description:Cell membrane homogenates (24 μg protein) were incubated at 22° C. for 60 minutes with 0.3 nM [3H]methyl-spiperone in the absence or presence of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: